Press release
Presbyopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight
Presbyopia Clinical Trials
(Albany, USA) DelveInsight's, "Presbyopia Pipeline Insight" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report provides a detailed description of the Presbyopia drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Discover the latest drugs and treatment options in the Presbyopia Pipeline. Dive into DelveInsight's comprehensive report today! @ Presbyopia Pipeline Outlook [https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Presbyopia Pipeline Report
* DelveInsight's Presbyopia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Presbyopia treatment.
* In April 2025, Tenpoint Therapeutics, Ltd. ("Tenpoint"), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BRIMOCHOL Trademark PF for the treatment of presbyopia, an age-related near-vision loss condition impacting approximately two billion people globally and 128 million people in the United States.
* In November 2024:- Alcon Research- The purpose of this study is to evaluate on-eye clinical performance of the investigational contact lenses following 30 days of wear in the intended population. Participants will be expected to attend 5 office visits for an individual duration of participation of approximately 64 days.
* In October 2024, LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for LNZ100 for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. The FDA noted that it is not planning to hold an advisory committee meeting to discuss this application.
* The leading Presbyopia Companies such as Glaukos Corporation, Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, among others.
* Promising Presbyopia Therapies such as LX-OPH-162, Research programme, STN 1013600, GLK-302, Nyxol, VTI-001, LNZ100, MicroLine (Pilocarpine Ophthalmic), CSF-1 (PresbiDrops), Nyxol, VT-101 (Brimochol), AGN-241622, and others.
Stay ahead with the most recent pipeline outlook for Presbyopia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Presbyopia Treatment Drugs [https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
Presbyopia Emerging Drugs Profile
- LNZ100: Lenz Therapeutics
LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, a selective muscarinic receptor agonist. It works by constricting the pupil, creating a pinhole effect that improves near vision. Unlike other pupil-constricting agents, aceclidine has a unique mechanism of action that decouples the miotic effect from the stimulation of the ciliary muscle, reducing the risk of myopic shift and accompanying brow ache. This allows LNZ100 to provide a broad patient population with a long-lasting and efficient treatment for presbyopia, a condition characterized by the gradual hardening of the lens and decline in near vision with age. Currently, the drug is in Phase III stage of its clinical trial for the treatment of presbyopia.
- GLK-302: Glaukos Corporation
Glaukos Corporation is developing GLK-302, a sterile ophthalmic topical cream containing the active ingredient pilocarpine, for the treatment of presbyopia. GLK-302 is designed to be applied to the eyelid, allowing the pilocarpine to be delivered through the dermis to the eye. The mechanism of action involves pilocarpine, a muscarinic acetylcholine receptor agonist, which acts on the M3 and M1 receptors in the eye to cause pupillary constriction and increase the depth of focus, thereby improving near visual acuity in presbyopic patients without significantly deteriorating distance vision. Currently, the drug is in Phase II stage of its clinical trial for the treatment of presbyopia.
Explore groundbreaking therapies and clinical trials in the Presbyopia Pipeline. Access DelveInsight's detailed report now! @ New Presbyopia Drugs [https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
Presbyopia Companies
Some of the leading companies working in the pipeline are Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio, and others.
Presbyopia Drugs ROA
Presbyopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Presbyopia Drug Molecule Type
Presbyopia Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Unveil the future of Presbyopia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Presbyopia Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
Presbyopia Treatment Outlook:
The Presbyopia treatment pipeline is gaining momentum due to several key drivers, including the rising global prevalence of age-related vision disorders, increasing awareness and diagnosis rates, and growing demand for non-invasive and convenient treatment options like eye drops and intraocular lenses. Technological advancements in ophthalmology and the emergence of novel pharmacological therapies are further accelerating pipeline activity. Moreover, favorable regulatory support and increased investments in R&D by pharmaceutical companies are fueling innovation in the presbyopia space.
However, barriers persist, such as the high cost of advanced treatments, limited long-term efficacy data for newer therapies, and challenges in patient compliance, especially for drop-based regimens. Additionally, intense competition among emerging therapies and a cautious adoption rate by clinicians may hinder rapid market penetration. Safety concerns and side effects associated with certain investigational drugs also pose significant hurdles in the clinical development process.
Scope of the Presbyopia Pipeline Report
* Coverage- Global
* Presbyopia Companies- Glaukos Corporation, Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, among others.
* Presbyopia Therapies- LX-OPH-162, Research programme, STN 1013600, GLK-302, Nyxol, VTI-001, LNZ100, MicroLine (Pilocarpine Ophthalmic), CSF-1 (PresbiDrops), Nyxol, VT-101 (Brimochol), AGN-241622, and others.
* Presbyopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Presbyopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Presbyopia Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Presbyopia Companies, Medication and Products [https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr]
Table of Content
1. Introduction
2. Executive Summary
3. Presbyopia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Presbyopia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. LNZ100: Lenz Therapeutics
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. GLK-302: Glaukos Corporation
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Preclinical Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report.....
18. Inactive Products
19. Presbyopia - Collaborations Assessment- Licensing / Partnering / Funding
20. Presbyopia - Unmet Needs
21. Presbyopia - Market Drivers and Barriers
22. Appendix
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=presbyopia-clinical-trials-analysis-2025-ema-pdma-fda-approvals-medication-therapies-nice-approvals-mechanism-of-action-roa-ind-nda-approval-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Presbyopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight here
News-ID: 3990420 • Views: …
More Releases from ABNewswire
Delhi-Based ContentKeon Expands Its Domain Leadership
In an era of interest-based digital engagement, ContentKeon continues to lead as a dynamic content writing employer in Delhi, presenting a vast spectrum of content writing offerings with established impact. By excelling in technical content material writing, content writing for sports, fashion, travel, and blogs, the organisation cements its position as a destiny-ahead companion for industry-specific content material achievement.
As the digital economy grows more and more numerous, ContentKeon, a trusted…
Plumbers from Foster Plumbing & Heating Provide Critical Support During Local Em …
In recent years, the demand for Foster Plumbers near me has grown significantly, particularly during storms, freezing temperatures, or infrastructure issues that lead to plumbing breakdowns.
Rapid Plumbing Response in Times of Crisis
When unexpected plumbing problems arise, having access to skilled professionals is essential for minimizing damage and restoring normalcy. Many residents search for Foster Cheap Plumbers Near Me [http://fosterpandh.com/] to find quick and affordable help during urgent situations. Known for…
Montgomery Roofing Recognized as Top Roofing Contractors in Lorena TX for Qualit …
When homeowners search for roofing contractors near me, they look for experience, professionalism, and lasting results. Montgomery Roofing - Lorena Roofers meets these expectations by using premium materials and proven techniques for residential and commercial projects. Whether replacing an aging roof or repairing storm damage, their team ensures precision at every step-from initial assessment to final inspection.
Lorena, TX - Montgomery Roofing has earned recognition as one of the premier roofing…
Cypress Pro Wash Sees Surge in Demand for Eco-Friendly Power Washing in Cypress, …
With growing awareness of environmental concerns, many Cypress residents are searching for a power washing company that balances effectiveness with eco-conscious practices. Traditional pressure washing methods often rely on harsh chemicals that can harm plants, pets, and local waterways. Cypress Pro Wash addresses these concerns by using biodegradable detergents and water-conserving techniques, ensuring a deep clean without unnecessary environmental impact.
Cypress, TX - Homeowners and businesses in Cypress are increasingly prioritizing…
More Releases for Presbyopia
Presbyopia Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Presbyopia Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Presbyopia pipeline landscape. It covers the Presbyopia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Presbyopia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Presbyopia…
Rising Geriatric Population Fuels Growth Of Myopia And Presbyopia Treatment Mark …
The Myopia and Presbyopia Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Myopia and Presbyopia Treatment Market Size and Projected Growth Rate?
The market size for myopia and presbyopia treatment has witnessed substantial growth over several recent years. The market is projected…
Presbyopia Treatment Market Trends And Industry Forecast 2024-2031
Presbyopia Treatment Market: Trends Shaping the Industry
The presbyopia treatment market is experiencing significant growth, driven by a surge in the global aging population. As people live longer, the demand for effective solutions to age-related vision problems like presbyopia increases. This trend is fueling research and development efforts, leading to the introduction of innovative therapeutics like advanced contact lenses and eye drops.
Market Segmentation: Addressing Diverse Needs
The presbyopia treatment market is segmented…
Presbyopia Treatment Market Growth Analysis 2023-2030
Global Presbyopia Treatment Market Gains Momentum Amidst Rising Aging Population and Innovations in Therapeutics:
The global presbyopia treatment market has witnessed substantial growth in recent years, fueled by the increasing prevalence of presbyopia and the expanding aging population. Presbyopia, a common vision loss associated with aging, has prompted a surge in demand for effective treatments, leading to advancements in eyeglasses, contact lenses, surgeries, eye drops, and nutrient-based interventions.
Refractive surgeries, including Conductive…
Presbyopia Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companie …
DelveInsight's, "Presbyopia Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Presbyopia Pipeline Insight Report
• Presbyopia Pipeline report offers a comprehensive…
Presbyopia Market 2020-2027 Sets the Table for Continued Growth || Top Growing C …
A transparent research method has been accomplished with the right tools and techniques to make this Presbyopia Market research report world-class. Two of the most widely used techniques namely SWOT analysis and Porter's Five Forces Analysis have been used while generating this report. Competitive analysis conducted in this report puts light on the moves of the key players in the Healthcare industry such as new product launches, expansions, agreements, joint…
